Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxVIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Clinical Trial for ADRX-0405 in Advanced Solid Tumors Including Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial for ASP1002, a bispecific antibody
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2 Adaptive ADT and Docetaxel Trial for mCSPC
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Clinical Trial: The PHAROS Trial Investigates Novel ACK1 Inhibitor
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Newsletter 30/2025 July 27, 2025
- New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets July 26, 2025
- Scientists Trace Deadly Shift in Prostate Cancer to Two Key Genes July 26, 2025
- Low-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising July 25, 2025